ALMU

Aeluma is a legitimate but very early-stage compound-semiconductor developer that has begun converting its wafer-scale photodetector platform into revenue — FY2025 sales of $4.67M grew +407.6% off a tiny base, and the loss narrowed to -$3.02M from -$4.56M. The balance sheet is genuinely clean for a company this young: $17.9M equity against just $1.51M total liabilities (0.08x), current assets of $17.3M vs. $705K current liabilities, and operating cash burn of only -$1.15M. The growth is underpinned by real government demand — an $11.7M DARPA heterogeneous-integration contract (invoiced in milestone tranches), plus NASA, DoE, and two U.S. Navy awards — which is why total assets and revenue both jumped ~400%+ in FY2025.

The problem is the price, not the business. At $18.85 the market cap is ~$300M against $4.67M of revenue — a P/S of 64.2 — while the company still runs a -45.9% operating margin and -64.8% net margin and has never turned a profit (accumulated deficit -$16.6M). That multiple already discounts years of flawless execution the filing explicitly warns against: management states Aeluma is 'recently formed and only in the early development stages,' is 'not in volume production for any of our product offerings,' and 'may experience continuing net losses and negative cash flows.' Government contracts are milestone-contingent revenue, not a durable commercial franchise, and the DARPA back half ($5.7M) is conditional on hitting milestones.